---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-283140"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2024-12-20T23:59:59+00:00"
generated_at: "2026-05-29T00:21:27.384655+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CEO Diana Brainard departs; President/CFO Vikas Sinha named CEO effective Dec 19, 2024

## Summary
- Diana Brainard resigned as CEO and director effective Dec 19; no disagreement with company on operations, policies, or practices.
- Vikas Sinha (President, CFO since 2019) appointed CEO and principal executive officer same day; he has over 20 years life sciences finance experience.
- Brainard receives $1.88M lump sum (36-mo salary), $376k target bonus, $100k merger completion bonus, and acceleration of 371,525 RSUs.
- Company previously disclosed proposed merger with Kalaris Therapeutics, Inc.; Sinha served as CFO of Alexion Pharma (ALXN) previously.

## SEC filing metadata
- accession: 0001193125-24-283140
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2024-12-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312524283140/0001193125-24-283140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312524283140/d905140d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-283140
- JSON: https://secwatch.observer/filing/0001193125-24-283140.json
- Plain text: https://secwatch.observer/filing/0001193125-24-283140.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.